Imago BioSciences shares are trading lower after the company presented data from the ongoing Phase 2 study of bomedemstat in essential thrombocythemia at ASH 2021.

by | Dec 13, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.